학술논문
Rationale and design of the EMPA-ELDERLY trial: A randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes
Document Type
Article
Author
Source
In: BMJ Open . (BMJ Open, 7 April 2021, 11(4))
Subject
Language
English
ISSN
20446055